115 related articles for article (PubMed ID: 34038857)
21. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.
Liang X; Liu X; Wang B; Zou F; Wang A; Qi S; Chen C; Zhao Z; Wang W; Qi Z; Lv F; Hu Z; Wang L; Zhang S; Liu Q; Liu J
J Med Chem; 2016 Mar; 59(5):1984-2004. PubMed ID: 26789553
[TBL] [Abstract][Full Text] [Related]
22. UNC569-induced Morphological Changes in Pigment Epithelia and Photoreceptor Cells in the Retina through MerTK Inhibition in Mice.
Sayama A; Okado K; Nakamura K; Kawaguchi T; Iguchi T; Makino T; Yabe K; Kai K; Mori K
Toxicol Pathol; 2018 Feb; 46(2):193-201. PubMed ID: 29310530
[TBL] [Abstract][Full Text] [Related]
23. Expression of TAM-R in Human Immune Cells and Unique Regulatory Function of MerTK in IL-10 Production by Tolerogenic DC.
Giroud P; Renaudineau S; Gudefin L; Calcei A; Menguy T; Rozan C; Mizrahi J; Caux C; Duong V; Valladeau-Guilemond J
Front Immunol; 2020; 11():564133. PubMed ID: 33101282
[TBL] [Abstract][Full Text] [Related]
24. MERTK is a host factor that promotes classical swine fever virus entry and antagonizes innate immune response in PK-15 cells.
Zheng G; Li LF; Zhang Y; Qu L; Wang W; Li M; Yu S; Zhou M; Luo Y; Sun Y; Munir M; Li S; Qiu HJ
Emerg Microbes Infect; 2020; 9(1):571-581. PubMed ID: 32172658
[TBL] [Abstract][Full Text] [Related]
25. MerTK mediates STAT3-KRAS/SRC-signaling axis for glioma stem cell maintenance.
Eom H; Kaushik N; Yoo KC; Shim JK; Kwon M; Choi MY; Yoon T; Kang SG; Lee SJ
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):87-95. PubMed ID: 29553850
[TBL] [Abstract][Full Text] [Related]
26. MerTK as a therapeutic target in glioblastoma.
Wu J; Frady LN; Bash RE; Cohen SM; Schorzman AN; Su YT; Irvin DM; Zamboni WC; Wang X; Frye SV; Ewend MG; Sulman EP; Gilbert MR; Earp HS; Miller CR
Neuro Oncol; 2018 Jan; 20(1):92-102. PubMed ID: 28605477
[TBL] [Abstract][Full Text] [Related]
27. Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy.
Crittenden MR; Baird J; Friedman D; Savage T; Uhde L; Alice A; Cottam B; Young K; Newell P; Nguyen C; Bambina S; Kramer G; Akporiaye E; Malecka A; Jackson A; Gough MJ
Oncotarget; 2016 Nov; 7(48):78653-78666. PubMed ID: 27602953
[TBL] [Abstract][Full Text] [Related]
28. Sulforaphane rescues amyloid-β peptide-mediated decrease in MerTK expression through its anti-inflammatory effect in human THP-1 macrophages.
Jhang KA; Park JS; Kim HS; Chong YH
J Neuroinflammation; 2018 Mar; 15(1):75. PubMed ID: 29530050
[TBL] [Abstract][Full Text] [Related]
29. MERTK Acts as a Costimulatory Receptor on Human CD8
Peeters MJW; Dulkeviciute D; Draghi A; Ritter C; Rahbech A; Skadborg SK; Seremet T; Carnaz Simões AM; Martinenaite E; Halldórsdóttir HR; Andersen MH; Olofsson GH; Svane IM; Rasmussen LJ; Met Ö; Becker JC; Donia M; Desler C; Thor Straten P
Cancer Immunol Res; 2019 Sep; 7(9):1472-1484. PubMed ID: 31266785
[TBL] [Abstract][Full Text] [Related]
30. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
Laufer R; Li SW; Liu Y; Ng G; Lang Y; Feher M; Brokx R; Beletskaya I; Hodgson R; Mao G; Plotnikova O; Awrey DE; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
Bioorg Med Chem Lett; 2016 Aug; 26(15):3562-6. PubMed ID: 27335255
[TBL] [Abstract][Full Text] [Related]
31. Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP.
Zhou Y; Fei M; Zhang G; Liang WC; Lin W; Wu Y; Piskol R; Ridgway J; McNamara E; Huang H; Zhang J; Oh J; Patel JM; Jakubiak D; Lau J; Blackwood B; Bravo DD; Shi Y; Wang J; Hu HM; Lee WP; Jesudason R; Sangaraju D; Modrusan Z; Anderson KR; Warming S; Roose-Girma M; Yan M
Immunity; 2020 Feb; 52(2):357-373.e9. PubMed ID: 32049051
[TBL] [Abstract][Full Text] [Related]
32. Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors.
Ding X; Dai X; Long K; Peng C; Andreotti D; Bamborough P; Eatherton AJ; Edge C; Jandu KS; Nichols PL; Philps OJ; Stasi LP; Wan Z; Xiang JN; Dong K; Dossang P; Ho MH; Li Y; Mensah L; Guan X; Reith AD; Ren F
Bioorg Med Chem Lett; 2017 Sep; 27(17):4034-4038. PubMed ID: 28774425
[TBL] [Abstract][Full Text] [Related]
33. Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancer.
Kostecki KL; Iida M; Wiley AL; Kimani S; Mehall B; Tetreault K; Alexandridis R; Yu M; Hong S; Salgia R; Bruce JY; Birge RB; Harari PM; Wheeler DL
Head Neck; 2023 May; 45(5):1255-1271. PubMed ID: 36939040
[TBL] [Abstract][Full Text] [Related]
34. Dead Cells Induce Innate Anergy via Mertk after Acute Viral Infection.
Adomati T; Cham LB; Hamdan TA; Bhat H; Duhan V; Li F; Ali M; Lang E; Huang A; Naser E; Khairnar V; Friedrich SK; Lang J; Friebus-Kardash J; Bergerhausen M; Schiller M; Machlah YM; Lang F; Häussinger D; Ferencik S; Hardt C; Lang PA; Lang KS
Cell Rep; 2020 Mar; 30(11):3671-3681.e5. PubMed ID: 32187540
[TBL] [Abstract][Full Text] [Related]
35. Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms.
Yang T; Hu M; Qi W; Yang Z; Tang M; He J; Chen Y; Bai P; Yuan X; Zhang C; Liu K; Lu Y; Xiang M; Chen L
J Med Chem; 2019 Nov; 62(22):10305-10320. PubMed ID: 31670517
[TBL] [Abstract][Full Text] [Related]
36. Potential Oncogenic Effect of the MERTK-Dependent Apoptotic-Cell Clearance Pathway in Starry-Sky B-Cell Lymphoma.
Farnworth-McHugh S; Barth N; Melville L; Paterson M; Lynch C; Holland P; Dransfield I; Gregory C
Front Immunol; 2020; 11():1759. PubMed ID: 32973744
[TBL] [Abstract][Full Text] [Related]
37. DBA/2J Haplotype on Distal Chromosome 2 Reduces Mertk Expression, Restricts Efferocytosis, and Increases Susceptibility to Atherosclerosis.
Kayashima Y; Makhanova N; Maeda N
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):e82-e91. PubMed ID: 28473436
[TBL] [Abstract][Full Text] [Related]
38. Pharmacophore-Based 3D-QSAR Modeling, Virtual Screening and Molecular Docking Analysis for the Detection of MERTK Inhibitors with Novel Scaffold.
Zhou S; Zhou L; Cui R; Tian Y; Li X; You R; Zhong L
Comb Chem High Throughput Screen; 2016; 19(1):73-96. PubMed ID: 26632441
[TBL] [Abstract][Full Text] [Related]
39. Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation.
Yu M; Long Y; Yang Y; Li M; Teo T; Noll B; Philip S; Wang S
Eur J Med Chem; 2021 Jun; 218():113391. PubMed ID: 33823391
[TBL] [Abstract][Full Text] [Related]
40. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
LaMontagne KR; Butler J; Borowski VB; Fuentes-Pesquera AR; Blevitt JM; Huang S; Li R; Connolly PJ; Greenberger LM
Angiogenesis; 2009; 12(3):287-96. PubMed ID: 19544081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
